A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System-Reference-Cited by-同舟云学术

A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System

Published:2010-03 Issue: Volume: Page:
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:

Author:

Paz-Ares L.,del Muro J. G.,Grande E.,Díaz S.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2710.2009.01135.x/fullpdf

Reference44 articles.

1. Cancer Statistics, 2008;Jemal;CA: A Cancer Journal for Clinicians,2007

2. Targeted therapy for metastatic renal cell carcinoma;Patel;British Journal of Cancer,2006

3. 4.Ministerio de Sanidad y Consumo. La situación del cáncer en España. Available at: http://www.msc.es/ciudadanos/enfLesiones/enfNoTransmisibles/cancer/home.htm (accessed 31 October 2007).

4. Rising incidence of renal cell cancer in the United States;Chow;JAMA,1999

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reassessing the cost-effectiveness of nivolumab for the treatment of renal cell carcinoma based on mature survival data, updated safety and lower comparator price;Journal of Medical Economics;2021-01-01

2. Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review;PharmacoEconomics;2018-11-23

3. A systematic review of economic evaluations of tyrosine kinase inhibitors of vascular endothelial growth factor receptors, mammalian target of rapamycin inhibitors and programmed death-1 inhibitors in metastatic renal cell cancer;Expert Review of Pharmacoeconomics & Outcomes Research;2018-03-13

4. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation;Health Technology Assessment;2018-01

5. Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy;PharmacoEconomics;2016-10-24